Can I test my risk of Alzheimer's with a blood test (p-tau217)?
A blood test for p-tau217 shows promising results as an early signal for Alzheimer's, but is not yet available as a routine test; discuss any concerns about memory or hereditary risk with your doctor.
Plasma p-tau217 is a protein that becomes measurably elevated in the blood in Alzheimer's disease and that correlates with the accumulation of harmful proteins in the brain. Across multiple cohorts, this blood test distinguishes Alzheimer's from other brain diseases with an accuracy comparable to cerebrospinal fluid tests and PET scans. That is remarkably good for a simple blood test.
In people with a rare hereditary Alzheimer's mutation, levels were already elevated some 20 years before the expected onset of first symptoms, well before anyone notices anything. This suggests that the test can detect early brain pathology. However, this applies to a specific hereditary group; whether the same holds true for people without such a mutation is not yet clear. In a diverse urban population, elevated levels were linked to a later Alzheimer's diagnosis, but that association does not yet prove causation.
Plasma p-tau217 also performs slightly better than a closely related measure (p-tau181), although the difference is small. The real threshold lies elsewhere: the test is not yet ready for use as a routine test at a general practitioner or neurologist. Validation in the general, broader population is still lacking. Experts agree that external confirmation is needed before the test can be widely deployed.
A practical caveat: several studies were conducted with the involvement, in whole or in part, of pharmaceutical companies that have a commercial interest in this test. That is not evidence of incorrect results, but it underscores why independent confirmation is so important before drawing conclusions from this data. If you have concerns about your memory or a family history of Alzheimer's, discuss with your doctor which tests are already worthwhile today.
This answer is based on multiple human studies, including large cohort studies and reviews of the existing literature. Diagnostic accuracy is consistently high across the available studies, but an independent systematic review establishes that broad validation in unselected population groups is still lacking. The finding regarding early detection (20 years before symptoms) comes from research in a small, genetically distinct group and cannot be straightforwardly extrapolated to the general population. Several studies were partly funded by or conducted with the involvement of Eli Lilly, which has a commercial interest in the development of p-tau tests.
Can Magnetic Resonance Spectroscopy (MRS) detect Alzheimer's disease early?
MRS can signal brain abnormalities in early Alzheimer's disease, but is not yet ready for use as a standalone diagnostic tool. As a complement to PET scanning and other biomarkers the technique is promising, but larger standardised studies are needed before it offers practical benefit to patients.
Which blood values should I have checked to age healthily?
Blood sugar, blood fats, and inflammation markers are best supported by the evidence if you want to age healthily. Alzheimer's blood tests are only meaningful when there are genuine memory or thinking problems, and always under the guidance of a specialist.
Is there a treatment in development that prevents Alzheimer's?
There are promising indications that an active lifestyle and treatment of risk factors such as high blood pressure and diabetes can reduce risk. Proven prevention does not yet exist, but starting on those modifiable factors now will in any case yield real health benefits.
Does type 2 diabetes increase your risk of dementia?
Type 2 diabetes substantially increases the risk of dementia, and the younger you are at diagnosis, the greater that risk. Good blood sugar management and the choice of medication appear to be relevant; discuss this with your doctor if you have diabetes.
How much do cholinesterase inhibitors help with cognitive decline in Alzheimer's?
In mild to moderate Alzheimer's disease, these medications measurably slow cognitive decline. The benefit is modest: side effects such as nausea cause nearly one in three people to discontinue treatment early.
Can high blood pressure in your 40s cause dementia later in life?
High blood pressure in your forties demonstrably increases your risk of dementia later in life, and early treatment appears to reduce that risk. Get your blood pressure checked and discuss with your GP whether treatment is worthwhile.